NOVEN NAMES JOEL LIPPMAN, M.D. AS VICE PRESIDENT – CLINICAL DEVELOPMENT & CHIEF MEDICAL OFFICER |
BackMiami, FL, July 14,
2008 -- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced
the appointment of Joel S. Lippman, M.D. as Vice President – Clinical
Development & Chief Medical Officer, effective immediately. In
this role, Lippman will lead all aspects of the clinical, regulatory
and medical affairs functions at Noven.
Lippman is an obstetrician-gynecologist
certified by the American Board of Obstetrics and Gynecology with nearly
20 years of clinical development and medical affairs experience in
the pharmaceutical and device industries. Prior to joining Noven, Lippman
served Ethicon, Inc., a Johnson & Johnson company, as Worldwide
Vice President – Medical Affairs & Chief Medical Officer
and as a member of that company’s Global Management Board. Previously,
he served Ortho-McNeil Pharmaceutical, Inc., also a Johnson & Johnson
company, as Vice President – Clinical Trials. Earlier, he served
Wyeth-Ayerst Laboratories in a number of clinical development, medical
affairs and related roles.
Lippman holds a Medical Degree from New
York Medical College and a Masters in Public Health from Harvard University
School of Public Health. He is a Fellow of the American College of
Obstetricians and Gynecologists, and is widely published in the areas
of menopausal hormone therapy, hormonal contraceptives and other women’s
health areas.
“Dr. Lippman’s appointment further expands
the industry experience of a Noven team committed to establishing Noven
as a high growth specialty pharmaceutical company,” said Peter
Brandt, Noven’s President & Chief Executive Officer. “He
will direct our clinical, regulatory and medical affairs activities
for both our transdermal and oral products, helping design and execute
our clinical plans, and leading developmental products through the
regulatory process toward commercialization. His experience in the
areas of women’s health and central nervous system conditions
complements our current areas of therapeutic focus, and his leadership
in product selection and development should help us execute on new
product opportunities that bring benefit to the company, to our partners
and customers, and to the patients who use our products.”
About
Noven
Noven Pharmaceuticals, Inc. is a specialty pharmaceutical company
engaged in the research, development, manufacture, marketing and sale
of prescription pharmaceutical products. Noven’s business and
operations are focused in three principal areas – transdermal
drug delivery, the Novogyne joint venture, and its Noven Therapeutics
specialty pharmaceutical unit.
Contact:
|
Copyright © 2008 Noven Pharmaceuticals, Inc. All rights reserved.